Meta-analysis of Bevacizumab Combined Cisplatin for Non-small Cell Lung Cancer with Malignant Pleural Effusion
CAI Qin
XIE Bi-yuan
HUANG Xue-wu
Abstract：Objective To evaluate the efficacy and safety of bevacizumab combined cisplatin for non-small cell lung cancer with malignant pleural effusion by meta-analysis.Methods Randomized control trial (RCT) on bevacizumab combined with cisplatin in treatment of malignant pleural effusion were selected from databases: Pubmed, Enbase, Cochrane Library, Chinese Biomedical Literature Dctabase, China National Knowledge Infrastructure(CNKI), Wanfang Database, Chinese VIP Journal Database, China Biology Medicine disc(CBMdisc) and so on.The literature were collected and independently evaluated by two evaluators using RevMan 5.3.Results Six RCTs were involved for a total of 371 patients.Meta-analysis results indicated that bevacizumab plus cisplatin obviously improved treatment efficacy (OR=3.40,95%CI:2.12~5.45, P<0.000 01) and markedly decreased the quantities of vascular endothelial growth factor (VEGF) in pleural effusion (MD=59.53, 95%CI:42.85~76.22, P<0.000 01).In addition, there was no difference in adverse events between bevacizumab groups and control groups.Conclusion Bevacizumab combine cisplatin intrapleural injection is obviously effective and safe in treatment of non-small cell lung cancer with malignant pleural effusion.
Keywords：BevacizumabCisplatinNon-small cell lung cancerMalignant pleural effusionMeta-analysis
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 259-263,266 )